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Context: Strontium ranelate reduces vertebral and nonvertebral fracture risk in postmenopausal
osteoporosis.
Objective:Theobjectiveof this studywas todeterminetheefficacyandsafetyof strontiumranelate
in osteoporosis in men over 2 years (main analysis after 1 year).
Design: Thiswas an international, unbalanced (2:1), double-blind, randomizedplacebo-controlled
trial (MALEO [MALE Osteoporosis]).
Setting: This international study included 54 centers in 14 countries.
Participants: Participants were 261 white men with primary osteoporosis.
Intervention: Strontium ranelate at 2 g/d (n  174) or placebo (n  87) was administered.
Main OutcomeMeasures: Lumbar spine (L2–L4), femoral neck, and total hip bonemineral density
(BMD), biochemical bone markers, and safety were measured.
Results: Baseline characteristics were similar in both groups in the whole population (age, 72.9
6.0 years; lumbar spine BMD T-score,2.7 1.0; femoral neck BMD T-score,2.3 0.7). Menwho
received strontiumranelateover2yearshadgreater increases in lumbar spineBMDthanthosewho
received placebo (relative change from baseline to end, 9.7%  7.5% vs 2.0%  5.5%; between-
groupdifferenceestimate (SE), 7.7% (0.9%); 95%confidence interval, 5.9%–9.5%;P .001). There
werealso significantbetween-groupdifferences in relative changes in femoralneckBMD(P .001)
and total hip BMD (P  .001). At the end of treatment, mean levels of serum cross-linked telo-
peptides of type I collagen, a marker of bone resorption, were increased in both the strontium
ranelate group (10.7% 58.0%; P .022) and the placebo group (34.9% 65.8%; P .001). The
corresponding mean changes of bone alkaline phosphatase, a marker of bone formation, were
6.4%  28.5% (P  .005) and 1.9%  25.4% (P  .505), respectively. After 2 years, the blood
strontium level (129  66 mol/L) was similar to that in trials of postmenopausal osteoporosis.
Strontium ranelate was generally well tolerated.
Conclusions: The effects of strontium ranelate on BMD in osteoporotic men were similar to those
in postmenopausal osteoporotic women, supporting its use in the treatment of osteoporosis in
men. (J Clin Endocrinol Metab 98: 592–601, 2013)
Osteoporosis in men is an important and expandinghealth care problem (1, 2), with serious conse-
quences in terms of fracture risk, morbidity, mortality,
and economic cost (3, 4). In a recent studyofmenadmitted
for long-term rehabilitation (5), nearly one-third (31%)
had osteoporosis (lumbar spine, total hip, or femoral neck
T-score 2.5). Mortality after osteoporotic vertebral,
nonvertebral, and hip fractures is even higher in men than
in women (6). Despite the fact that osteoporosis in men is
increasingly recognizedas apublic health issue, thedisease
remains underdiagnosed and undertreated (7–9). A recent
analysis in an American community–based male cohort
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found that if National Osteoporosis Foundation criteria
for treatment were applied, more than one-third (34%) of
white US men older than 65 years and nearly one-half
(49%) of white US men older than 75 years would be
candidates for osteoporosis drug therapy (9).
Pharmacological and nonpharmacological options ex-
ist for osteoporosis inmen. As for osteoporosis inwomen,
nonpharmacological options include restoration of mus-
cle function and strength, fall prevention, and discontin-
uation of smoking and excess alcohol consumption (2).
Current pharmacological treatments for osteoporosis
in women—alendronate, risedronate, zoledronate, and
teriparatide—have been demonstrated to be effective in
men, using surrogate endpoints such as bonemineral den-
sity (BMD) and bone turnover markers (10–15). It would
seem, therefore, that the response to current treatments is
independent of sex.
Strontium ranelate reduces vertebral and nonvertebral
fracture risk in a wide range of postmenopausal women
with documented osteoporosis (16–18), irrespective of
age (19, 20) or severity of the underlying disease (21). A
strong link between increased BMD and reduced fracture
risk was also demonstrated in postmenopausal women
treated with strontium ranelate (22). Although its molec-
ular mechanism of action is yet to be fully elucidated, in
preclinical and clinical studies, strontium ranelate has
been shown to promote osteoblastic cell differentiation in
vitro and to improve bone architecture and tissue quality
in vivo (23–25). In addition, it directly inhibits osteoclastic
differentiation and activity and modulates the OPG-
RANK-RANK ligand system in vitro (26).
MALEO (MALEOsteoporosis) is the first randomized
placebo-controlled trial in men designed to investigate
whether treatmentwith strontium ranelate is effective and
safe in increasing BMD in men with osteoporosis. The
protocol of this bridging study was established in compli-
ance with the European Medicines Agency (EMA) guide-
lines (27). Regulatory approval of an osteoporosis drug
for use in men, both from the US Food and Drug Admin-
istration and the EMA, requires evidence from bridging
studies of treatment effects on intermediate endpoints
suchasBMDsimilar to those shown to reduce fracture risk
in postmenopausal women. The primary objective of this
2-year study (main analysis at 1 year) was to investigate
whether 2 g/d strontium ranelate had similar efficacywith
regard to lumbar spine BMD in a male population with
fracture risk comparable to that in postmenopausal
women in pivotal strontium ranelate studies (16, 17).
Materials and Methods
Trial description
This international, multicenter, unbalanced (2:1), random-
ized, double-blind, placebo-controlled study involved patients
with primary osteoporosis from54 active centers in 14 countries
in South Africa, Australia, Europe, and North America and
lasted 2 years. An unbalanced 2:1 randomization ratio in favor
of strontiumranelatewas chosen for ethical reasons to reduce the
number of patients exposed to placebo. The main study analysis
took place after 1 year and a secondary analysis after 2 years.
Ethical approval was received, and all patients gave written in-
formed consent at selection. The study was conducted in accor-
dance with the ethical principles stated in the Declaration of
Helsinki of 1964 (amended in Tokyo in 2004). The trial is reg-
istered on http://www.controlled-trials.com (2006-006086-16).
Patients
The study population consisted of ambulatory white men
aged 65 years with low lumbar spine (L2–L4) BMD (0.840
g/cm2withaHologicdual x-rayabsorptiometry [DXA]deviceor
0.949 g/cm2 with a GE Lunar DXA device; T-score, 2.5)
and/or low femoral neck BMD (0.600 g/cm2 Hologic or
0.743 g/cm2 GE Lunar; T-score, 2.4) and at least one risk
factor for osteoporotic fracture (including age75 years, prev-
alent grade 1 vertebral fracture, previous low trauma fracture,
family history of osteoporotic fracture, smoking 15 ciga-
rettes/d, known lowBMD, and low bodymass index [BMI]20
kg/m2). BMD cutoffs corresponded to those used in the large-
scale pivotal randomized controlled trials of strontium ranelate
in postmenopausal osteoporotic women (16, 17). Criteria for
exclusion at the selection visit included a history of or increased
risk for venous thromboembolism, severe hypogonadism, skel-
etal diseases (such as secondary osteoporosis, Paget disease, os-
teomalacia, hyperparathyroidism, and hypoparathyroidism),
and previous treatment acting on bone metabolism (including
long-term oral or inhaled glucocorticoid treatment in the previ-
ous year, bisphosphonate injection in the previous year or tablets
in the previous 18 months, calcitriol and 1-vitamin D in the
previous 6 months, and parathyroid hormone or derivatives, ie,
teriparatide). Patients were not included if they had severe os-
teoporosis (T-score4.0 at any site),2 prevalentmild (grade
1 using the Genant semiquantitative scoring method) and/or
moderate (grade 2) osteoporotic vertebral fractures, or any se-
vere osteoporotic vertebral fracture (grade 3). The first patient
visit was on December 11, 2007, and recruitment ended on
March 2, 2009. The last patient visit was on March 4, 2011.
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Treatments
Randomization via an interactive voice system was stratified
by country and unbalanced (2:1) in favor of strontium ranelate.
Patients were allocated to 2 g/d strontium ranelate or placebo
orally (1 sachet daily with water at bedtime) for 2 years. Patients
and investigators were blinded to treatment allocation, and the
study treatments were identically packaged and labeled. All pa-
tients (except thosewith hypercalciuria4mg/kg/24 h) received
calcium and vitamin D supplementation (1 g 800 IU daily) for
2 years from the selection visit.
Endpoints
The primary endpoint was lumbar spine (L2–L4) BMD at 1
year. Secondary endpoints included lumbar spine BMD at 2
years and hip (femoral neck and total hip) BMD, biochemical
bone markers (bone alkaline phosphatase [b-ALP] and serum
cross-linked telopeptides of type I collagen [s-CTX]), quality of
life (QOL), and safety (including fracture assessment by system-
atic spinal x-ray at 2 years) at both 1 year and 2 years.
Measurements
DXA was used to measure BMD at baseline and every 6
months thereafter (or earlier if patients withdrew before 6
months), using two types of DXA device (Hologic and GE Lu-
nar). Quality control monitoring of DXA devices was done on a
daily basis. For both types of device, the uncorrected average
coefficient of variation was 0.4%  0.1%. Each device was
cross-calibrated using an external, standardized phantom (Eu-
ropean Spine Phantom) to obtain optimal concordance between
measurements fromdifferent centers (28). The lumbar spinewas
scanned in an anterior-posterior projection. Both hips were also
scanned in an antero-posterior position at baseline, and there-
after only the hip with the lowest BMD at baseline (or the intact
hip in cases of hip fracture or prosthesis) was scanned. DXA
scanswere analyzed at a central reading center (Qualim,Geneva,
Switzerland). Hologic male reference values were used to calcu-
late lumbar spine (L2–L4), femoral neck, and total hip T-scores.
BMD data from GE Lunar DXA devices were converted using
standardized formulas (29, 30).
Serum markers of bone turnover, b-ALP (a marker of bone
formation) and s-CTX (amarker of bone resorption), weremea-
suredatbaselineandat3,6, 12,18, and24months (fastingblood
sample). QOL was evaluated by assessing back pain and its im-
pact on daily life, using corresponding questions from the
QUALIOST questionnaire at baseline and every 6months there-
after (31). Each patient was asked 4 questions: Have you had
pain in the middle or upper part of your back?; Have you had
pain when walking or climbing stairs?; Have you experienced
discomfort when staying in the same position for a long time
(sitting, standing)?; and Has pain interfered with your sleep?
Adverse events were monitored, as were clinical and laboratory
parameters (including blood strontium levels). Safety evaluation
included recording of clinical fracture at selection, at 3 months,
and every 6 months thereafter and vertebral x-ray assessment of
thoracic/lumbar vertebral fracture using the Genantmethod at a
central reading center (CEMO,HoˆpitalCochin, Paris, France) at
selection and at 24 months. Prevalent fracture was identified by
the existence of any vertebral fracture–induced deformity (grade
1 [mild deformity] or greater) at baseline. Incident fracture was
defined as fracture that occurred in vertebrae that were normal
(grade 0) at baseline.
Statistical methods
Sample size was estimated based on the relative change in
lumbar spine BMD from baseline to the last available postbase-
line value over 12 months for an estimated difference between
strontium ranelate and placebo, using a 2-sided Student t test for
independent samples with 5% type I error. A common SDof 6%
was assumed. To establish a statistically significant between-
group difference of3%with90% power, 191 patients were
needed (127 strontium ranelate and 64 placebo).When the 15%
withdrawal/protocol violation rate expected during the first year
was factored in, 221 patients were needed (147 strontium
ranelate and 74 placebo). The statistical analysis plan for the
24-month analysis was finalized before study unblinding. The
randomized set was defined as all included patients who were
randomly assigned to therapy (N  261). The full analysis set
was defined as all randomly assigned patients who took at least
1 dose of study treatment from inclusion to 24 months, had at
least 1 baseline lumbar spine BMD value, and had at least 1
postbaseline lumbar spine BMD value up to 24 months.
Baseline characteristics are presented as descriptive statistics
with numbers andpercentages for qualitative data or asmeans
SDs for quantitative data. The efficacy analysis was done on the
full analysis set and was based on intention to treat. Intergroup
differences in the relative change from baseline to end were an-
alyzed using a general linear model with country as covariate to
produce an estimate (E) of the treatment group difference, SE of
the estimate with the associated 95% confidence interval (CI)
and P value. A sensitivity analysis on the primary endpoint was
done using a general linear model adjusted for age and prevalent
vertebral fracture. The treatment effect on secondary endpoints
was studied using a general linearmodel with country (and base-
line value when the change from baseline was studied) as cova-
riate and using a nonparametric approach (Hodges-Lehmann
estimator) for the bone markers (nonnormal distribution). The
samemodelswere provided for the relative change frombaseline
to each visit. The safety set was defined as all patients who took
at least one dose of the study treatment from inclusion to 24
months. Results were analyzed by theMethodology andClinical
Data Analysis Division of Institut de Recherches Internationales
Servier using SAS software (version 9.1).
Results
The trial profile is shown in Figure 1. Of the 384 patients
selected, 261 were included and randomly assigned (174
strontium ranelate and 87 placebo). Most patient with-
drawals were due to adverse events (33 of 174 [19%]with
strontium ranelate and 13 of 87 [15%] with placebo, re-
spectively) or nonmedical reasons (19 of 174 [11%] with
strontium ranelate vs 11 of 87 [13%] with placebo); 117
patients completed 24 months of treatment on strontium
ranelate versus 63 with placebo. There were 243 patients
in the full analysis set (93% of the randomized set). Pa-
tients excluded from the full analysis set (13 of 174 [8%]
strontiumranelate and5of87 [6%]placebo)weremissing
either a baseline lumbar spine BMD value or a postbase-
line lumbar spine BMD value. There were 260 patients in
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the safety set (1 patient was excluded because he never
took the treatment).
Thebaseline characteristics of the twogroupswere sim-
ilar (Table 1). Mean age was 72.9 6.0 years, mean BMI
was 25.5 3.7 kg/m2, andmean time since diagnosis was
26.6 48.6 months in the whole population. Mean lum-
bar spine BMD T-score was 2.7  1.0, and mean fem-
oral neck BMD T-score was 2.3 
0.7. Fewer than one-third of patients
(29%) had a prevalent osteoporotic
vertebral fracture at baseline,whereas a
small minority (11%) had a previous
peripheral osteoporotic fracture. Al-
most one-third of patients (32%) re-
ported at least one previous treatment
that could have modulated bone me-
tabolism, the most common of which
were mineral supplements, ie, calcium
(23%), vitamins (12%, mainly vitamin
D and analogs [11%]), and drugs for
the treatment of bone disease (12%,
principally bisphosphonates [11%]).
Levels of 25-hydroxyvitamin D3
were similar in the strontium ranelate
(62.2  17.2 nmol/L) and placebo
(62.8  18.6 nmol/L) groups at base-
line, and 76% of patients had a level of
25-hydroxyvitamin D3 50 nmol/L.
Levels of testosterone were also similar in the two groups
(18.2  5.9 and 18.6  6.9 nmol/L, respectively), and
97% of patients had a level of testosterone8.6 nmol/L.
Levels of bonemarkerswere also comparable;mean levels
of b-ALP were 13.0  5.0 ng/mL (median, 12.1 ng/mL;
minimum, 10.0 ng/mL; maximum, 14.8 ng/mL) and
Figure 1. Trial profile. FAS, full analysis set.
Table 1. Baseline Characteristicsa
Parameter Strontium Ranelate Placebo All P Valueb
Randomized set
n 174 87 261
Age, y 73.1  6.1 72.6  5.7 72.9  6.0 .54
Height, cm 169  7 171  7 170  7 .12
BMI, kg/m2 25.2  3.6 26.0  4.1 25.5  3.7 .11
Time since diagnosis of osteoporosis, mo 24.5  45.3 30.8  54.6 26.6  48.6 .35
Prevalent vertebral osteoporotic fracture 53 (31)c 22 (25) 75 (29) .38
Previous peripheral osteoporotic fracture 20 (12) 9 (10) 29 (11) .78
Drugs for treatment of bone diseased 22 (13) 9 (10) 31 (12) .59
Current smokers 16 (9) 13 (15) 29 (11) .16
Current alcohol consumption 91 (52) 53 (61) 144 (55) .19
Full analysis set
n 161 82 243
Lumbar spine BMD 161 (100) 82 (100) 243 (100)
BMD, g/cm2 0.81  0.10 0.83  0.13 0.82  0.11 .11
T-score 2.8  0.9 2.6  1.2 2.7  1.0
Femoral neck BMD 154 (96) 78 (95) 232 (95)
BMD, g/cm2 0.62  0.09 0.62  0.10 0.62  0.09 .80
T-score 2.3  0.6 2.3  0.7 2.3  0.7
Total hip BMD 154 (96) 78 (95) 232 (95)
BMD, g/cm2 0.78  0.12 0.79  0.12 0.78  0.12 .82
T-score 1.7  0.8 1.6  0.8 1.7  0.8
a Values are mean  SD or n (%).
b P value for strontium ranelate vs placebo (Student t test).
c Assessment for 1 patient was missing.
d Mainly bisphosphonates (97%).
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13.3  4.6 ng/mL (median, 12.4 ng/mL; minimum, 9.8
ng/mL; maximum, 15.6 ng/mL) in the strontium ranelate
group (n 158) and placebo group (n 79), respectively,
at baseline. Mean levels of s-CTX were 0.5  0.3 ng/mL
(median, 0.4 ng/mL;minimum, 0.3 ng/mL;maximum, 0.6
ng/mL) and 0.4  0.2 ng/mL (median, 0.4 ng/mL; mini-
mum, 0.3 ng/mL; maximum, 0.5 ng/mL) in the same
groups. There were no relevant differences between the
randomized set and full analysis set.
Mean treatment duration was 19.2  8.4 months.
Compliance was 91% 15% with strontium ranelate vs
92%  11% with placebo.
The analysis over 1 year showed that lumbar spine (L2–
L4) BMD, the primary endpoint, was significantly greater
inmenwho received strontium ranelate (from0.820.10
g/cm2 at baseline in that group to 0.88  0.11 g/cm2 at
end) than inmenwho received placebo (from 0.85 0.14
g/cm2 to 0.86 0.13 g/cm2). The relative changes for the
two groupswere 7.1% 6.0%with strontium ranelate vs
1.7% 4.4%with placebo, from baseline to end, and the
between-groupdifferenceEwas5.3%(SE,0.8%;95%CI,
3.9%–6.8%; P  .001).
Over2years, theaverage increase in lumbar spineBMD
was significantly greater in men who received strontium
ranelate than in men who received placebo. The relative
changes for the twogroupswere 9.7%7.5%with stron-
tiumranelate vs2.0%5.5%withplacebo, frombaseline
to end; the between-group difference E was 7.7% (SE,
0.9%; 95% CI, 5.9%–9.5%; P  .001) (Table 2). The
sensitivity analysis confirmed the results (E, 7.6%; SE,
0.9%; 95%CI, 5.8%–9.5%; P .001). At every visit (12
and 24 months), there were greater increases in mean rel-
ative changes in lumbar spine, femoral neck, and total hip
BMD with strontium ranelate than with placebo, which
were significant from 12 months onward (all P  .001)
(Figure 2 and Table 2). Lumbar spine, femoral neck, and
total hip BMD increased by 9.8%, 3.3%, and 3.7% after
24 months in men treated with strontium ranelate vs pla-
cebo (all P  .001) (Table 2).
Mean levels of s-CTX were lower in the strontium
ranelate group than in the placebo group from 3 months
onward (P  .001). The relative change from baseline to
end was 10.7%  58.0% (P  .022) in the strontium
ranelate group vs 34.9%  65.8% (P  .001) in the pla-
cebo group (estimate of the adjusted means between-
group difference,22.2%; 95% CI,33.3% to8.3%;
P .001) (Table 3).Meanwhile, the relative changes from
baseline to end of b-ALP were 6.4% 28.5% (P .005)
in the strontium ranelate group vs 1.9%  25.4% (P 
.51) in the placebo group (estimate of the adjusted means
between-group difference, 5.4%; 95% CI, 0.9% to
11.3%; P  .10). Blood strontium levels had reached a
steady state in the strontium ranelate group by 3 months
(137  65 mol/L), and levels were maintained up to 24
months (138  69 and 129  66 mol/L at the 12- and
24-month visits).
There was a trend toward a better QOL (ie, a decrease
in score) with strontium ranelate from baseline to study
end (E, 0.13; 95% CI, 0.27 to 0.01; P  .072 vs pla-
cebo) (Table 4). Moreover, there was a significant im-
provement in QOLwith strontium ranelate from baseline
to 24 months (P  .009). More patients receiving stron-
Table 2. Mean Percentage Changes in BMD From Baseline to 12 Months, 24 Months, and Study End in Men
Receiving Strontium Ranelate or Placebo
Site
Mean % Change in
BMD (95% CI)
% Treatment-Placebo
Difference (95% CI)a P Valueb
Strontium Ranelate
(n  161)
Placebo
(n  82)
Baseline to 12 mo
Lumbar spine 8.2 (7.1 to 9.2) 1.9 (0.9 to 3.0) 6.3 (4.7 to 7.9) .001
Total hip 3.0 (2.2 to 3.9) 1.0 (0.4 to 1.6) 2.1 (0.9 to 3.2) .001
Femoral neck 3.5 (2.6 to 4.3) 0.4 (0.8 to 1.5) 3.2 (1.8 to 4.6) .001
Baseline to 24 mo
Lumbar spine 11.9 (10.6 to 13.2) 2.1 (0.6 to 3.6) 9.8 (7.8 to 11.9) .001
Total hip 3.7 (2.7 to 4.8) 0.1 (1.1 to 1.2) 3.7 (2.0 to 5.3) .001
Femoral neck 4.4 (3.4 to 5.5) 1.1 (0.4 to 2.6) 3.3 (1.5 to 5.1) .001
Baseline to study endc
Lumbar spine 9.7 (8.5 to 10.9) 2.0 (0.8 to 3.2) 7.7 (5.9 to 9.5) .001
Total hip 3.2 (2.3 to 4.0) 0.1 (0.9 to 1.0) 3.1 (1.8 to 4.5) .001
Femoral neck 3.8 (2.9 to 4.6) 1.0 (0.3 to 2.2) 2.8 (1.3 to 4.2) .001
a Analysis of covariance with treatment and baseline BMD as covariates (intention to treat population) where difference is the least squares mean.
b P value for strontium ranelate vs placebo (Student t test, general linear model).
c Value at the last postbaseline visit (until 24 mo) with treatment. When there was no postbaseline visit (until 24 mo) with treatment, the end value
corresponds to the first available value.
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tium ranelate had improvement in pain in the middle/
upper part of back (32% vs 23%; P  .28), pain when
walking/climbing stairs (23% vs 15%; P .39), and dis-
comfort in the same position (35% vs 27%; P .36) than
patients receiving placebo; this improvement was
significant for pain interfering with sleep (17% vs 4%;
P  .019).
The safety set included 173 men receiving strontium
ranelate and 87 men receiving placebo. Fewer patients
reported at least one emergent adverse event with stron-
tium ranelate (88%) than with placebo (97%) (P  .03)
(Table 5). Themost frequently reported treatment-related
adverse event during the study was hypertension (18 of
173 [10.4%] vs 10 of 87 [11.5%]). Although there ap-
peared to be some imbalance in the incidence of coronary
artery disorders (angina pectoris and coronary artery dis-
ease) between the strontium ranelate and placebo groups
(15 of 173 [8.7%] vs 4 of 87 [4.6%]), it should be noted
that there was a similar imbalance in the relevant medical
histories between the groups (21% in the strontium
ranelate group vs 16% in the placebo group), in particular
for myocardial ischemia (10.3% vs 3.4%). Comparable
incidences of gastrointestinal disorders were reported in
both groups (30.1% with strontium ranelate group vs
29.9% with placebo). No participants in either group re-
ported DRESS (drug rash with eosinophilia and systemic
symptoms), Stevens-Johnson syndrome, or toxic epider-
mal necrolysis. Two cases of deep vein thrombosis (in-
cluding 1 treatment-related case in the first year) and 1
case of nontreatment-related pulmonary embolism (in the
second year) were reported with strontium ranelate. All
patients had recovered at the end of the study.Overall, the
incidence of adverse events considered to be drug-related
was similar in both groups (56 of 173 [28.9%] vs 26 of 87
[29.9%]). Most adverse events in each treatment group
were either mild or moderate; severe adverse events were
reported by 5.4% of men receiving strontium ranelate vs
7.4%ofmen receiving placebo.More adverse events lead-
ing to drugwithdrawal were reported bymen in the stron-
tium ranelate group (31 of 173 [17.9%] vs 12 of 87
[13.8%]). However, these generally occurred within the
first 6 months of treatment and corresponded to gastro-
intestinal disorders or skin and subcutaneous disorders,
which are known side effects of strontium ranelate (32). In
the case of skin reactions, it is recommended that treat-
ment be stopped. Four deaths were reported during the
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Figure 2. Relative change in lumbar spine (A), femoral neck (B), and total hip (C) BMD of the strontium ranelate and placebo groups over 2 years
in the full analysis set. Bars are 95% CI.
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treatment period: 3 (1.7%) in the strontium ranelate
group (septic shock, sudden death, and death of unknown
cause in patients who had a strong history of cardiac dis-
orders) and 1 (1.1%) in the placebo group (cerebral hem-
orrhage). None were considered to be related to study
medication. Radiographic vertebral fracturewas reported
in 7 of 120 (5.8%) men receiving strontium ranelate vs 5
of 64 (7.8%) men receiving placebo (nonsignificant).
Discussion
MALEO is the first randomized placebo-controlled clin-
ical study to evaluate the efficacy and safety of strontium
ranelate in a population of treatment-naive osteoporotic
menwith low BMD.Our study population has the typical
features of a population ofmenwith osteoporosis in terms
of age, BMI, and T-score at baseline (5). Treatment with
strontium ranelate in this population was associated with
significant increases in BMD at the lumbar spine, femoral
neck, and total hip throughout the study comparedwith
placebo. These changes in BMD were comparable in
magnitude to those observed previously in postmeno-
pausal osteoporotic women treated with strontium
ranelate (16, 17).
All previously approvedpharmacological treatmentsof
osteoporosis inmen, ie, bisphosphonates and teriparatide,
Table 3. Mean Percentage Changes in b-ALP and s-CTX From Baseline to Each Visit in Men Receiving Strontium
Ranelate or Placeboa
Change from
Baseline
Strontium Ranelate
(n  161)b
Placebo
(n  82)b
Treatment-Placebo
Difference (95% CI)c P Valued
Mean change in b-ALP (%)
3 mo 1.3  19.9 5.6  16.8 4.2 (0.5 to 8.2) .07
(n  146, P  .44) (n  79, P  .004)
12 mo 2.5  22.1 5.1  23.2 3.1 (2.0 to 8.3) .23
(n  125, P  .22) (n  71, P  .071)
24 mo 8.1  31.7 4.7  24.7 2.4 (5.3 to 10.1) .57
(n  110, P  .008) (n  59, P  .153)
Study end 6.4  28.5 1.9  25.4 5.4 (0.9 to 11.3) .10
(n  158, P  .005) (n  79, P  .51)
Mean change in s-CTX (%)
3 mo 5.4  42.2 11.8  54.5 14.3 (25.0 to 0.0) .001
(n  146, P  .12) (n  78, P  .059)
12 mo 2.7  53.9 23.8  70.9 25.0 (33.3 to 8.3) .001
(n  125, P  .58) (n  71, P  .006)
24 mo 11.3  54.4 40.9  69.1 25.0 (41.7 to 10.0) .001
(n  110, P  .032) (n  59, P  .001)
Study end 10.7  58.0 34.9  65.8 22.2 (33.3 to 8.3) .001
(n  158, P  .022) (n  79, P  .001)
a Values are means  SD.
b P values indicated are for within-group changes vs baseline (Student t test).
c Hodges-Lehmann estimator for the difference between group means.
d Mann-Whitney-Wilcoxon test.
Table 4. QOL in Patients Who Had QOL Assessment in the Full Analysis Seta
Strontium Ranelate
(n  161)
Placebo
(n  82)
QUALIOST score
Baseline 1.62  0.73 1.51  0.60
End 1.36  0.58 1.45  0.62
Change from baseline to end 0.26  0.71 0.05  0.54
E (SE) 95% CI 0.13 (0.07) 0.27 to 0.01, P  .072b
Patients with improvement in QUALIOST itemc
Pain in middle/upper part of back 47 (32) 18 (23)
Pain when walking/climbing stairs 34 (23) 12 (15)
Discomfort in the same position 52 (35) 21 (27)
Pain interfering with patient sleep 25 (17)d 3 (4)
a Values are mean  SD or n (%).
b P value for strontium ranelate vs placebo (Student t test; general linear model).
c For patients with available data (n  149 strontium ranelate and n  78 placebo).
d P  .019 vs placebo (Cochran-Mantel-Haenszel test).
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have been investigated in clinical trials with BMD as a
surrogate endpoint (10–12, 14). BMD is known to predict
osteoporotic fracture in men, independent of age, body
weight, or prevalent fracture (33, 34). With regard to
strontium ranelate, changes in femoral neck BMD have
been linked toa reduction in vertebral andhip fracture risk
(22, 35). In postmenopausal osteoporosis, the 3-year in-
crease in BMD with strontium ranelate explains a large
part (76%) of the reduction in vertebral fracture rate ob-
served during treatment (22). Our findings suggest that
strontium ranelate may have antifracture efficacy in men
with osteoporosis.
The dosage of strontium ranelate used in our study (2
g/d) was the same as that used in the trials in osteoporotic
women (16, 17). After 2 years, mean levels of blood stron-
tium in the men in the active treatment arm of this study
(129  66 mol/L) were similar to those (118  79 and
134  88 mol/L) in the strontium ranelate–treated
women in those trials, SOTI (Spinal Osteoporosis Ther-
apeutic Intervention) andTROPOS (Treatment of Periph-
eral Osteoporosis) (16, 17), and, as with those studies,
blood strontium levels remained constant during the
study.
Although the levels of bone resorption markers ap-
peared to be lower with strontium ranelate than with pla-
cebo and those of bone formation markers were main-
tained, the small sample size made true trends hard to
discern. Although there are likely to be differences in the
pathogenesis of osteoporosis inmenandwomen (1, 2, 36),
the behavior of bone markers in male osteoporotic pa-
tients treated with strontium ranelate compared with
those inpatients treatedwithplacebowas compatiblewith
that observed in postmenopausal osteoporotic women
(16). No sex differences were expected with regard to the
mechanism of action on bone metabolism, because stron-
tium ranelate is not a hormonal treatment.
BMD treatment responses in studies of bisphospho-
nates and teriparatide in men with osteoporosis (10–12,
14) are generally similar to those observed in studies of
postmenopausal osteoporosis. The present study now ex-
tends these findings to show that there is also a similar
response in osteoporotic men and postmenopausal
women with strontium ranelate. Our findings also con-
firm those of a previous 1-year open-label study in men
(strontium ranelate vs alendronate), which showed that
treatment with strontium ranelate increased BMD after 1
year (37). As in postmenopausal osteoporotic women
(38), QOL results indicate an improvement in QOL in
patients treated with strontium ranelate compared with
placebo. The positive trend was confirmed over 24
months, particularly with regard to pain that interfered
with sleep.
Strontium ranelate was generally well tolerated, and
adverse events reported were similar to those reported in
osteoporosis studies in postmenopausal women. A few
cases of coronary artery disorders occurred during the
study, but these occurred in patientswith relevantmedical
histories of coronary artery disease, which was unevenly
distributed between the groups.
Certain limitations are worth discussing. Strontium
ranelate has been shown to be safe in general and effective
in postmenopausal women up to 10 years (39); the dura-
tion of the current study was short in comparison. Only
whitemenwere included in this study; however, treatment
Table 5. Overall Safety Profile and Most Common (5%) Adverse Events in the Strontium Ranelate Groupa
Adverse Event
Strontium Ranelate
(n  174)
Placebo
(n  87) P Valueb
Any emergent adverse event 153 (88.4) 84 (96.6) .03
Emergent adverse events leading to study drug withdrawalc 31 (17.9) 12 (13.8) .40
Any drug-related emergent adverse events 50 (28.9) 26 (29.9) .87
Any serious emergent adverse events 51 (29.5) 26 (29.9) .95
Fatal emergent adverse events 3 (1.7) 1 (1.1) 1.00
Adverse events 5% in the strontium ranelate group
Hypertension 18 (10.4) 10 (11.5) .79
Back pain 15 (8.7) 11 (12.6) .31
Fall 12 (6.9) 7 (8.0) .75
Hypercalciuria 11 (6.4) 5 (5.7) .85
Arthralgia 10 (5.8) 10 (11.5) .10
Bronchitis 10 (5.8) 4 (4.6) .78
Nasopharyngitis 9 (5.2) 9 (10.3) .12
Spinal osteoarthritis 9 (5.2) 6 (6.9) .58
Pruritus 9 (5.2) 4 (4.6) 1.00
Cataract 9 (5.2) 2 (2.3) .35
a Values are n (%).
b P value for strontium ranelate vs placebo (2 test if all theoretical frequencies 5% and the Fisher test otherwise).
c Excluding sudden deaths.
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with strontiumranelatehasalsobeen showntobeeffective
in non-whitewomen (40). Although the current studywas
not powered to assess fracture incidence, after 2 years
vertebral fracture incidence (central x-ray reading) was
lower in the strontium ranelate group than in the placebo
group. As discussed earlier, our chosen surrogate primary
endpoint, lumbar spine BMD, has been used as a primary
endpoint in most randomized controlled trials in osteo-
porosis in men, and documentation of a link between in-
creased BMD and reduced fracture risk in women treated
with strontium ranelate reinforces the use of BMD as a
surrogate endpoint (22). The high degree of variability of
the biomarker results, particularly in the placebo group,
precludedany further conclusionabout themodeof action
of strontium ranelate beyond current knowledge (26).
In summary, the effects of strontium ranelate on BMD
suggest that the impact of strontium ranelate on fracture
risk is likely to be sex-independent. Two years of stron-
tium ranelate therapy inmenwith lowBMDwas generally
well tolerated and increased BMD at all skeletal sites as-
sessed. The effects of strontium ranelate treatment on
BMD in this study were similar to those previously shown
to be associated with fracture risk reduction in women
with postmenopausal osteoporosis (16, 17). Strontium
ranelate has recently been approved by the EMA for the
treatment of osteoporosis in men at increased risk of frac-
ture (41).
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